Share Price and Basic Stock Data

Last Updated: November 26, 2024, 8:19 pm

Market Cap	56.3 Cr.
Current Price	75.9
High / Low	94.9/25.8
Stock P/E	21.6
Book Value	11.9
Dividend Yield	0.00 %
ROCE	9.72 %
ROE	3.44 %
Face Value	10.0
PEG Ratio	0.48

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Gujarat Terce Laboratories Ltd

Competitors of Gujarat Terce Laboratories Ltd

Stock Name	Market Cap	Current Price	High / Low	Stock P/E	Book Value	Dividend Yield	ROCE	ROE	Face Value
Gujarat Themis Biosyn Ltd	3,552 Cr.	326	390/108	67.4	20.5	0.20 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	56.3 Cr.	75.9	94.9/25.8	21.6	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	27.8 Cr.	19.0	19.5/8.35	36.1	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	86.2 Cr.	115	155/87.0	12.9	55.4	0.00 %	12.7 %	15.5 %	10.0
Glenmark Life Sciences Ltd	13,082 Cr.	1,068	1,335/625	30.9	207	2.11 %	28.1 %	21.1 %	2.00
Industry Average	19,261.91 Cr	1,203.11		56.90	184.91	0.32%	16.36%	16.88%	6.61

All Competitor Stocks of Gujarat Terce Laboratories Ltd

Quarterly Result

Month	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Sales	10.13	10.75	9.32	9.41	12.58	11.90	12.89	10.72	12.03	13.02	12.21	11.89	13.30
Expenses	9.60	10.11	11.00	11.09	12.98	11.77	13.08	11.85	11.48	12.18	11.20	11.81	11.64
Operating Profit	0.53	0.64	-1.68	-1.68	-0.40	0.13	-0.19	-1.13	0.55	0.84	1.01	0.08	1.66
OPM %	5.23%	5.95%	-18.03%	-17.85%	-3.18%	1.09%	-1.47%	-10.54%	4.57%	6.45%	8.27%	0.67%	12.48%
Other Income	0.08	0.07	0.09	0.07	0.10	0.08	0.10	0.08	0.08	0.08	0.08	0.07	0.08
Interest	0.10	0.10	0.15	0.20	0.22	0.14	0.17	0.17	0.20	0.16	0.15	0.13	0.13
Depreciation	0.05	0.06	0.12	0.07	0.07	0.07	0.16	0.09	0.09	0.09	0.09	0.09	0.09
Profit before tax	0.46	0.55	-1.86	-1.88	-0.59	0.00	-0.42	-1.31	0.34	0.67	0.85	-0.07	1.52
Tax %	0.00%	14.55%	-11.29%	0.00%	0.00%		-290.48%	0.00%	0.00%	0.00%	35.29%	14.29%	1.97%
Net Profit	0.45	0.48	-1.66	-1.88	-0.59	0.00	0.80	-1.31	0.33	0.67	0.54	-0.08	1.48
EPS in Rs	0.61	0.65	-2.24	-2.53	-0.80	0.00	1.08	-1.77	0.44	0.90	0.73	-0.11	1.99

Last Updated: November 6, 2024, 6:35 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	79.02	28.84	26.48	25.00	25.29	29.01	31.03	37.54	25.18	40.13	46.78	47.92	49.15
Expenses	78.05	27.89	25.70	24.84	25.21	28.68	30.54	36.86	27.77	39.02	48.94	46.65	46.67
Operating Profit	0.97	0.95	0.78	0.16	0.08	0.33	0.49	0.68	-2.59	1.11	-2.16	1.27	2.48
OPM %	1.23%	3.29%	2.95%	0.64%	0.32%	1.14%	1.58%	1.81%	-10.29%	2.77%	-4.62%	2.65%	5.05%
Other Income	0.05	0.13	0.08	0.19	0.44	0.41	0.32	0.29	0.62	0.31	0.35	0.32	0.31
Interest	0.43	0.41	0.41	0.38	0.31	0.23	0.25	0.29	0.39	0.40	0.72	0.68	0.64
Depreciation	0.32	0.33	0.16	0.19	0.19	0.19	0.21	0.24	0.18	0.28	0.36	0.37	0.36
Profit before tax	0.27	0.34	0.29	-0.22	0.02	0.32	0.35	0.44	-2.54	0.74	-2.89	0.54	1.79
Tax %	29.63%	29.41%	72.41%	209.09%	150.00%	15.62%	-25.71%	36.36%	-0.39%	-17.57%	-42.21%	55.56%
Net Profit	0.19	0.24	0.09	-0.67	-0.01	0.27	0.43	0.28	-2.52	0.87	-1.67	0.24	1.46
EPS in Rs	0.26	0.32	0.12	-0.90	-0.01	0.36	0.58	0.38	-3.40	1.17	-2.25	0.32	1.96
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	26.32%	-62.50%	-844.44%	98.51%	2800.00%	59.26%	-34.88%	-1000.00%	134.52%	-291.95%	114.37%
Change in YoY Net Profit Growth (%)	0.00%	-88.82%	-781.94%	942.95%	2701.49%	-2740.74%	-94.14%	-965.12%	1134.52%	-426.48%	406.33%

Gujarat Terce Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	5%
5 Years:	9%
3 Years:	24%
TTM:	6%

Compounded Profit Growth
10 Years:	0%
5 Years:	-11%
3 Years:	28%
TTM:	1550%

Stock Price CAGR
10 Years:	27%
5 Years:	54%
3 Years:	77%
1 Year:	155%

Return on Equity
10 Years:	-3%
5 Years:	-6%
3 Years:	-2%
Last Year:	3%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 2:35 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	7.42	7.42	7.42	7.42	7.42	7.42	7.42	7.42	7.42	7.42	7.42	7.42	7.42
Reserves	3.28	3.52	3.61	2.94	2.64	2.98	3.41	3.69	0.24	1.11	-0.56	-0.31	1.44
Borrowings	9.09	8.74	8.21	7.13	7.00	0.37	0.68	2.60	4.74	6.67	7.27	3.87	3.95
Other Liabilities	5.65	6.24	7.06	6.98	6.59	8.69	7.94	8.80	9.47	12.19	14.39	12.29	12.03
Total Liabilities	25.44	25.92	26.30	24.47	23.65	19.46	19.45	22.51	21.87	27.39	28.52	23.27	24.84
Fixed Assets	6.32	6.13	6.48	6.34	6.17	1.88	2.06	2.29	2.45	4.29	3.99	3.69	3.68
CWIP	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.00	0.00	0.30	0.30	0.24	0.27	0.29	0.27	0.27	0.27	0.27	0.27	0.00
Other Assets	19.12	19.77	19.52	17.83	17.24	17.31	17.10	19.95	19.15	22.83	24.26	19.31	21.16
Total Assets	25.44	25.92	26.30	24.47	23.65	19.46	19.45	22.51	21.87	27.39	28.52	23.27	24.84

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	3.99	0.46	1.38	0.16	0.24	4.58	-0.61	-1.59	-0.16	-0.44	0.03	2.60
Cash from Investing Activity +	-0.88	-0.27	0.08	-0.13	0.18	1.11	-0.13	-0.27	-0.42	-0.87	0.62	-0.46
Cash from Financing Activity +	-2.07	-0.74	-0.73	-1.43	-0.36	-5.39	0.20	1.72	1.83	1.53	-0.12	-4.08
Net Cash Flow	1.04	-0.55	0.73	-1.39	0.06	0.29	-0.55	-0.14	1.24	0.22	0.52	-1.94

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-8.12	-7.79	-7.43	-6.97	-6.92	-0.04	-0.19	-1.92	-7.33	-5.56	-9.43	-2.60

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	21.76	116.56	126.81	123.81	114.31	57.62	53.29	68.16	74.94	49.75	62.34	43.11
Inventory Days	42.17	112.27	142.73	162.86	150.01	126.33	114.69	90.00	136.65	153.90	83.56	82.12
Days Payable	10.13	58.79	88.41	92.30	59.70	110.67	85.26	83.44	104.13	96.22	110.35	97.39
Cash Conversion Cycle	53.79	170.04	181.14	194.37	204.61	73.29	82.72	74.72	107.46	107.43	35.56	27.84
Working Capital Days	45.41	130.61	132.74	133.59	108.53	23.15	33.99	48.32	48.42	46.57	25.12	14.70
ROCE %	3.43%	3.80%	3.39%	0.87%	1.91%	2.95%	5.39%	5.79%	-15.09%	8.26%	-14.80%	9.72%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoters	36.22%	36.22%	36.22%	36.22%	36.22%	36.22%	36.45%	36.65%	36.78%	37.01%	37.03%	37.03%
Public	63.78%	63.78%	63.78%	63.78%	63.80%	63.78%	63.54%	63.35%	63.22%	62.99%	62.97%	62.97%
No. of Shareholders	13,277	13,320	13,406	13,670	13,599	13,625	13,579	13,499	13,404	13,327	13,203	13,394

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE / ROE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	0.33	-2.25	1.18	-3.40	0.37
Diluted EPS (Rs.)	0.33	-2.25	1.18	-3.40	0.37
Cash EPS (Rs.)	0.82	-1.76	1.55	-3.16	0.69
Book Value[Excl.RevalReserv]/Share (Rs.)	9.58	9.25	11.50	10.32	14.97
Book Value[Incl.RevalReserv]/Share (Rs.)	9.58	9.25	11.50	10.32	14.97
Revenue From Operations / Share (Rs.)	64.65	63.05	54.09	33.93	50.60
PBDIT / Share (Rs.)	2.14	-2.44	1.92	-2.65	1.31
PBIT / Share (Rs.)	1.64	-2.93	1.55	-2.89	0.98
PBT / Share (Rs.)	0.73	-3.90	1.01	-3.41	0.58
Net Profit / Share (Rs.)	0.32	-2.25	1.18	-3.40	0.37
PBDIT Margin (%)	3.30	-3.86	3.54	-7.80	2.58
PBIT Margin (%)	2.54	-4.64	2.85	-8.50	1.93
PBT Margin (%)	1.13	-6.18	1.86	-10.05	1.16
Net Profit Margin (%)	0.50	-3.57	2.17	-10.00	0.73
Return on Networth / Equity (%)	3.42	-24.35	10.22	-32.89	2.48
Return on Capital Employeed (%)	10.95	-18.22	8.09	-21.08	5.57
Return On Assets (%)	1.04	-5.85	3.18	-11.55	1.23
Long Term Debt / Equity (X)	0.13	0.21	0.26	0.05	0.01
Total Debt / Equity (X)	0.54	1.06	0.78	0.59	0.22
Asset Turnover Ratio (%)	1.85	1.67	1.63	1.14	1.80
Current Ratio (X)	0.92	0.96	1.17	1.03	1.28
Quick Ratio (X)	0.59	0.69	0.68	0.70	0.91
Inventory Turnover Ratio (X)	1.80	1.11	1.40	0.95	1.43
Interest Coverage Ratio (X)	2.35	-2.51	3.55	-5.05	3.32
Interest Coverage Ratio (Post Tax) (X)	1.36	-1.32	3.18	-5.47	1.95
Enterprise Value (Cr.)	43.07	17.60	26.07	8.45	7.19
EV / Net Operating Revenue (X)	0.89	0.37	0.64	0.33	0.19
EV / EBITDA (X)	27.12	-9.74	18.31	-4.30	7.41
MarketCap / Net Operating Revenue (X)	0.81	0.26	0.48	0.20	0.12
Price / BV (X)	5.53	1.80	2.27	0.67	0.42
Price / Net Operating Revenue (X)	0.81	0.26	0.48	0.20	0.12
EarningsYield	0.01	-0.13	0.04	-0.48	0.05

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Gujarat Terce Laboratories Ltd as of November 27, 2024 is: 9.02

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 27, 2024, Gujarat Terce Laboratories Ltd is Overvalued by 88.12% compared to the current share price 75.90

Intrinsic Value of Gujarat Terce Laboratories Ltd as of November 27, 2024 is: 13.06

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 27, 2024, Gujarat Terce Laboratories Ltd is Overvalued by 82.79% compared to the current share price 75.90

Last 5 Year EPS CAGR: 44.77%

*Investments are subject to market risks

Strength and Weakness

Strength

Weakness

The stock has a low average ROCE of 1.30%, which may not be favorable.
The stock has a high average Working Capital Days of 65.93, which may not be favorable.
The stock has a high average Cash Conversion Cycle of 109.41, which may not be favorable.
The company has higher borrowings (5.41) compared to reserves (2.15), which may suggest financial risk.
The company has not shown consistent growth in sales (37.80) and profit (-0.04).

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gujarat Terce Laboratories Ltd:
1. Net Profit Margin: 0.5%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 10.95% (Industry Average ROCE: 16.21%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 3.42% (Industry Average ROE: 16.41%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 1.36
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.59
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 21.6 (Industry average Stock P/E: 45.94)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.54
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Gujarat Terce Laboratories Ltd. is a Public Limited Listed company incorporated on 28/03/1985 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24100GJ1985PLC007753 and registration number is 007753. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 40.13 Cr. and Equity Capital is Rs. 7.42 Cr. for the Year ended 31/03/2022.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	122/2, Ravi Estate, Gandhinagar District Gujarat 382729	gtll.factory@gmail.com http://www.gujaratterce.in

Management
Name	Position Held
Mr. Natwarbhai P Prajapati	Chairman
Mr. Amrutbhai P Prajapati	Whole Time Director
Mr. Aalap Prajapat	Managing Director & CEO
Mrs. Chhayaben A Shah	Independent Director
Mr. Viplav S Khamar	Independent Director
Mr. Surendra Kumar Sharma	Independent Director
Mr. Navinchandra Patel	Independent Director

FAQ

What is the latest intrinsic value of Gujarat Terce Laboratories Ltd?

The latest intrinsic value of Gujarat Terce Laboratories Ltd as on 27 November 2024 is ₹9.02, which is 88.12% lower than the current market price of ₹75.90.

What is the Market Cap of Gujarat Terce Laboratories Ltd?

The Market Cap of Gujarat Terce Laboratories Ltd is 56.3 Cr..

What is the current Stock Price of Gujarat Terce Laboratories Ltd as on 27 November 2024?

The current stock price of Gujarat Terce Laboratories Ltd as on 27 November 2024 is 75.9.

What is the High / Low of Gujarat Terce Laboratories Ltd stocks in FY 2024?

In FY 2024, the High / Low of Gujarat Terce Laboratories Ltd stocks is 94.9/25.8.

What is the Stock P/E of Gujarat Terce Laboratories Ltd?

The Stock P/E of Gujarat Terce Laboratories Ltd is 21.6.

What is the Book Value of Gujarat Terce Laboratories Ltd?

The Book Value of Gujarat Terce Laboratories Ltd is 11.9.

What is the Dividend Yield of Gujarat Terce Laboratories Ltd?

The Dividend Yield of Gujarat Terce Laboratories Ltd is 0.00 %.

What is the ROCE of Gujarat Terce Laboratories Ltd?

The ROCE of Gujarat Terce Laboratories Ltd is 9.72 %.

What is the ROE of Gujarat Terce Laboratories Ltd?

The ROE of Gujarat Terce Laboratories Ltd is 3.44 %.

What is the Face Value of Gujarat Terce Laboratories Ltd?

The Face Value of Gujarat Terce Laboratories Ltd is 10.0.